MedTrace Logo

Personalized Lifestyle Program in Treatment Resistant Irritable Bowel Syndrome

NCT05028036 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-06-22

No results posted yet for this study

Summary

Patients with treatment resistant irritable bowel syndrome (IBS) are recruited from secondary care gastroenterology clinics in Stockholm and screened for eligibility criteria. Participants follow a 12 month treatment program at Nordic Clinic, a clinic offering personalized lifestyle interventions based on the functional medicine model. In parallel with the treatment program, the participant are clinically assessed for the evaluation of the treatment after 6 months, 12 months, 18 months and 24 months

Conditions

  • Irritable Bowel Syndrome

Interventions

OTHER

Personalized lifestyle treatment program

The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components: * Dietary changes * Supplements * Measures to improve sleep / circadian rhythm * Stress management * Physical exercise The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program.

Sponsors & Collaborators

  • Stockholm University

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Greger Lindberg · Karolinska Institutet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-14
Primary Completion
2024-09-14
Completion
2025-09-14

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028036 on ClinicalTrials.gov